Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03880240 · ClinicalTrials.gov registry record · Phase 1
Gamma Induction for Alzheimer's Disease
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03880240: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT03880240 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03880240, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. Amyloid-β and tau are proteins that build up in the brain that may contribute to memory problems. The evidence suggests that both amyloid and tau play a critical role in AD and interventions that reliably and safely decrease the intracerebral burden of amyloid or tau could potentially be of marked clinical importance. Currently, therapeutic options are very limited and while there are pharmacologic interventions that transiently improve cognitive function, there are no treatments that alter disease progression. The purpose of this study is to see if multiple daily sessions of non-invasive brain stimulation can affect brain activity to decrease the amount of amyloid and tau in people with AD as compared to Sham (placebo) stimulation. The type of brain stimulation that will be used is called transcranial alternating current stimulation (tACS). This study will investigate different doses of tACS (2-4 weeks) and assess safety. The hope is that tACS will decrease the amount of amyloid and tau and improve memory and thinking in people with AD.
Interventions
- DEVICE Transcranial Alternating Current Stimulation (tACS)
- OTHER Sham Transcranial Alternating Current Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2019-08-05 |
| Est. Completion | 2024-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03880240
The ClinicalTrials.gov registry entry for NCT03880240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Transcranial Alternating Current Stimulation (tACS) is the first listed.
NCT03880240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03880240 about?
NCT03880240 is a clinical study titled "Gamma Induction for Alzheimer's Disease". Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. Amyloid-β and tau are proteins that build up in the brain that may contribute to memory problems. The evidence suggests that both amyloid a...
What is the current status of trial NCT03880240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2019-08-05. Estimated completion is 2024-11-30.
What interventions are being tested in trial NCT03880240?
The interventions under investigation include: Transcranial Alternating Current Stimulation (tACS) (DEVICE), Sham Transcranial Alternating Current Stimulation (OTHER).
Who is sponsoring clinical trial NCT03880240?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.